Obesity is the most common chronic disease in Western societies, with serious metabolic, cardiovascular, and psychosocial consequences. The therapeutic landscape has changed fundamentally: new-generation GLP-1 agonists achieve weight loss that, just a few years ago, was reserved solely for bariatric surgery. This presents physicians with a clear task: to understand obesity as a biologically based chronic disease and to treat it accordingly.
Autoren
- PD Dr. med. Dr. rer. nat. Sita Arjune
- Prof. Dr. med. Ruth Hanßen
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases
Pooled Expertise for Targeted Evaluation and Treatment
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa
Promoting Wound Healing with Gene Therapies and Birch Bark Extract
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- Psoriasis Research: What's in the Pipeline?
Highly selective oral TYK inhibitors in Phase III
- Cardiometabolism